ArticleCancers2022

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

Tadashi Nishimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.